Key Elements Chinese Pharmaceutical Companies and Biotech Firms Must Master to Succeed in Western‑Style Regulatory Inspections
- Elizabeth Zybczynski
- Jun 12
- 4 min read
The Chinese pharmaceutical industry is rapidly transforming from a producer of lower‑cost
generics to an innovator of new drugs for increasingly complex treatments. The shift has been so significant that nearly half of the drugs entering human trials in the first half of 2025 originated from Chinese biopharma companies. This surge in innovation—combined with a dramatic increase in global licensing deals—is positioning China to become a pivotal contributor not only in pharmaceutical manufacturing but also in drug development and new therapy discovery in the decade ahead.
While China clearly possesses the technological, scientific, and innovative capabilities needed for success, companies must also master the skills required to gain regulatory approvals and maintain cGMP compliance to the satisfaction of Western regulators. Achieving this requires more than simply complying with regulations that are gradually harmonizing but still differ in important ways. Chinese pharmaceutical and biotech firms must be able to navigate the nuanced differences of Western inspections.
Understanding the Differences
Key differences between Chinese and Western inspections that must be managed include:
Inspection Timing
Inspection Content
Inspection Style
Inspection Language
Differences in Timing
NMPA pre‑approval inspections (PAIs) involve rigorous reviews of product design, application content, and the facility’s cGMP compliance. In contrast, Western‑style PAIs—particularly those conducted by the FDA—tend to focus more narrowly on three areas:
Alignment of the production process with the application
Readiness for commercial production, largely demonstrated through process validation data
Data integrity, including data traceability and analytical method review
Because of this focus, broader cGMP topics may not be deeply evaluated until a post‑launch inspection, which may occur one or more years after approval. It is critical that Chinese firms remain inspection‑ready for topics that may not have been previously tested and whose vulnerabilities may be unknown.
Differences in Content
During an NMPA inspection, much of the inspectors’ attention is directed toward detailed compliance with the Product Technical Requirements (PTR), the dossier, and specific Chinese standards (GB/YY + ISO). Western inspections, however, place their emphasis on interpretations of governing documents—FDA published guidance for the U.S. and EudraLex (based on PIC/S) for the EU and MHRA.
These differences result not only in variations in regulatory requirements but also in how compliance is explained, justified, and interpreted during an inspection.
A facility that is well‑practiced in NMPA‑style inspections may unintentionally fail to address the concerns of a Western investigator. Simple misunderstandings can lead to investigator frustration, which can quickly escalate into mistrust—an extremely difficult situation to recover from once it begins.
Subject Matter Experts (SMEs) must understand both the letter and the intent of FDA guidance documents and PIC/S annexes. They must also have sufficient practice explaining their products and processes within this framework.
Differences in Style
One of the most remarkable aspects of Chinese culture is its communal nature and the collaboration that emerges from it. This collaborative spirit fuels much of the innovation occurring across Chinese industries. If you have not seen the video of the construction of a massive hospital in just 10 days during COVID‑19, it is worth watching—it is a powerful example of coordinated teamwork.
However, in a Western regulatory inspection, this collaborative approach can create the wrong impression. It is common in China for a group of SMEs to discuss a question collectively and for the most senior person to provide the final answer. Unfortunately, to a Western investigator—especially one who does not speak the language—this can appear as though the answer is being “invented” on the spot.
For FDA, MHRA, or EU inspections, the most knowledgeable SME should be prepared and practiced in answering questions directly, using documentation as support—not relying on a group discussion. Communication may occur directly or through a translator, but it should remain a one‑on‑one exchange.
Differences in Language
Depending on how one counts “a word,” English contains between 500,000 and 600,000 dictionary entries—far more than most languages. This matters because a single Chinese word may map to multiple English words with different meanings to a native English speaker.
It is essential to have strong translators or multiple bilingual employees available during an inspection. Beyond accurate translation, it is critical to ensure that the context of important terms is conveyed. This allows both parties to detect misunderstandings early rather than continuing under incorrect assumptions.
For example, consider the words “verification” and “validation”—a distinction that is critical in an inspection. Now translate “validation” into Simplified Chinese using Google.
Then translate it back into English. The result is concerning.
To avoid this, SMEs should reinforce context when speaking. For example: “When we talk about process validation, we are referring to the objective evidence created to demonstrate that the finished product consistently meets its specifications.” This ensures that even if the word is mistranslated, the concept remains clear.
How to Build the Bridge
The most effective way to ensure continuous readiness for FDA, MHRA, or EU inspections is to conduct simulated Western‑style inspections. As the saying goes: “Practice doesn’t make perfect; it makes permanent. Only perfect practice makes perfect.”
Training Chinese teams in Western regulations, expectations, and inspection mechanics – and giving them repeated opportunities to practice – is the only path to predictable and reliable success.
Given the growing importance of the pharmaceutical industry to both the Chinese economy and the global healthcare landscape, nothing less will suffice.
A‑Z Continuous Compliance helps medical device and pharmaceutical organizations implement a six‑phase inspection readiness model that prevents regulatory observations, strengthens regulatory trust, and avoids the massive cost of reactive remediation. We specialize in helping Chinese sites bridge the gap between their experience with NMPA inspections and the expectations of FDA, MHRA, and EU authorities.